Company profile
Candel Therapeutics
An off-the-shelf multimodal biological immunotherapy company empowering the patient's immune system to fight cancer.
- Industry
- Biotechnology Research
- Employees
- 91
- Headquarters
- Needham, Massachusetts
- Founded
- 1999
- LinkedIn followers
- 13,779
- Office locations
- 1
Candel Therapeutics company summary
Candel Therapeutics is a company in the Biotechnology Research industry, headquartered in Needham, Massachusetts, founded in 1999. On LinkedIn the company has around 91 employees and 13,779 followers. Its listed specialties include Immuno-oncology, Oncology, Viral Immunotherapy, Prostate Cancer, Brain Cancer.
What technology does Candel Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Candel Therapeutics
Candel ($CADL) is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). In addition, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). For more information, visit www.candeltx.com or contact us at info@candeltx.com.
Specialties
Where is Candel Therapeutics located?
Candel Therapeutics lists 1 location.
Compare companies similar to Candel Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Candel Therapeutics candeltx.com | Biotechnology Research | 91 | 1999 | Needham, Massachusetts |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Candel Therapeutics
What does Candel Therapeutics do?
Candel ($CADL) is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). In addition, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). For more information, visit www.candeltx.com or contact us at info@candeltx.com.
How many employees does Candel Therapeutics have?
Candel Therapeutics has around 91 employees on LinkedIn.
Where is Candel Therapeutics headquartered?
Candel Therapeutics is headquartered in Needham, Massachusetts.
When was Candel Therapeutics founded?
Candel Therapeutics was founded in 1999.
Build a lead list from companies like Candel Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.